Inhibrx Biosciences, Inc. INBX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $101.37M-10.3% | $113.03M-6.6% | $121.05M-7.9% | $131.4M-25.7% | $176.77M-13.2% | ||
| $22.98M-1.3% | $23.3M-32.2% | $34.38M-7.1% | $37.01M-70.1% | $123.96M-3.1% | ||
| $124.35M-8.8% | $136.33M-12.3% | $155.43M-7.7% | $168.42M-44.0% | $300.72M-9.3% | ||
| $124.35M-8.8% | $136.33M-12.3% | $155.43M-7.7% | $168.42M-44.0% | $300.72M-9.3% | ||
| -$123.05M+8.9% | -$135.03M+12.3% | -$154.03M+7.8% | -$167.02M+44.4% | -$300.52M+9.3% | ||
| $13.02M+6.7% | $12.2M+35.3% | $9.01M+54.6% | $5.83M-27.6% | $8.05M-40.3% | ||
| -$7.13M-41.8% | -$5.03M-377% | -$1.05M-132% | $3.32M-99.8% | $2.02B+0.2% | ||
| -$130.18M+7.0% | -$140.05M-30.6% | -$107.22M+7.4% | -$115.83M-107% | $1.77B+2.0% | ||
| $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | $2K0.0% | ||
| -$130.19M+7.0% | -$140.06M-30.6% | -$107.22M+7.4% | -$115.83M-107% | $1.77B+2.0% | ||
| -$8.39+7.2% | -$9.04-30.4% | -$6.93+7.5% | -$7.49-106% | $119.84+2.5% | ||
| -$8.39+7.2% | -$9.04-30.4% | -$6.93+7.5% | -$7.49-106% | $121.46+2.5% | ||
| 62M+0.2% | 61.9M+0.8% | 61.4M0.0% | 61.4M+1.1% | 60.7M+3.1% | ||
| 62M+0.2% | 61.9M+1.1% | 61.2M0.0% | 61.2M+1.4% | 60.4M+3.1% | ||
| —— | $7.55M-10.1% | $8.4M-9.2% | $9.24M-8.4% | $10.09M-7.7% | ||
| —— | —— | —— | —— | —— | ||
| -$343K+10.0% | -$381K-35.1% | -$282K-44.6% | -$195K-332% | $84K+12.0% | ||
| -$123.05M+8.9% | -$135.03M+12.3% | -$154.03M+7.8% | -$167.02M+44.4% | -$300.52M+9.3% | ||
| -$120.71M+8.9% | -$132.54M+12.5% | -$151.42M+7.8% | -$164.23M+44.9% | -$297.93M+9.5% | ||
| -$120.71M+8.9% | -$132.54M+12.5% | -$151.42M+7.8% | -$164.23M+44.9% | -$297.93M+9.5% | ||
| -$123.05M+8.9% | -$135.03M+12.3% | -$154.03M+7.8% | -$167.02M+44.4% | -$300.52M+9.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Inhibrx Biosciences, Inc.'s revenue?
- Inhibrx Biosciences, Inc. (INBX) generated $1.3M in revenue over the trailing twelve months, up 550.0% year over year.
- Is Inhibrx Biosciences, Inc. profitable?
- Inhibrx Biosciences, Inc. is not currently profitable: it reported a net loss of $130.2M over the trailing twelve months, a -10773.5% net margin.
- What is Inhibrx Biosciences, Inc.'s earnings per share?
- Inhibrx Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-8.39.
- Where does Inhibrx Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
